Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS: In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. RESULTS: Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication. CONCLUSIONS: The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“(% [95% CI])† 44 (61 [49–72]) 4 (11 [3–25]) 12 (52 [31–73]) 1 (10 [0–45])”
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Not reported 1 (1) 1 (3) 1 (1) 1 (2) 2 (1)”
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“>ULN 15 (21) 7 (19) 24 (25) 11 (23) 35 (25)”
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 3×
“Stable disease 9 (12) 13 (35) 3 (13) 1 (10)”
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“M1b 22 (31) 8 (22) 27 (28) 12 (26) 39 (27)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 4×
“Increased lipase 12 (13) 8 (9) 2 (4) 1 (2)”
InfluentialSelf-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citation
Cited by
Items 301–400 of 1,008
New immunotherapies targeting the PD-1 pathway
Chinai, J. M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., & Zang, X. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.005 · Cited by 189
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Vigarios, E., Epstein, J. B., & Sibaud, V. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3629-4 · Cited by 189
Is CD47 an innate immune checkpoint for tumor evasion?
Liu, X., Kwon, H., Li, Z., & Fu, Y.-X. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0381-z · Cited by 185
Immune checkpoint inhibitors and elderly people: A review
Daste, A., Domblides, C., Gross-goupil, M., Chakiba, C., Quivy, A., Cochin, V., de Mones, E., Larmonier, N., Soubeyran, P., & Ravaud, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.044 · Cited by 188
In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf
Hammerich, L., Binder, A., & Brody, J. D. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.016 · Cited by 187
The Pancreatic Cancer Microenvironment
Dougan, S. K. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000288 · Cited by 187
Recent progress in Lynch syndrome and other familial colorectal cancer syndromes
Boland, P. M., Yurgelun, M. B., & Boland, C. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21448 · Cited by 188
Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis
Ma, P., Liu, J., Qin, J., Lai, L., Heo, G. S., Luehmann, H., Sultan, D., Bredemeyer, A., Bajapa, G., Feng, G., et al. (2024) · Circulation · doi:10.1161/circulationaha.122.062551 · Cited by 187
Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000829 · Cited by 186
Mucosal melanoma of the head and neck
Ascierto, P. A., Accorona, R., Botti, G., Farina, D., Fossati, P., Gatta, G., Gogas, H., Lombardi, D., Maroldi, R., Nicolai, P., et al. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.019 · Cited by 185
Callahan, M. K., Kluger, H., Postow, M. A., Segal, N. H., Lesokhin, A., Atkins, M. B., Kirkwood, J. M., Krishnan, S., Bhore, R., Horak, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2850 · Cited by 186
Self-citationCurrent issues and perspectives in PD-1 blockade cancer immunotherapy
Chamoto, K., Hatae, R., & Honjo, T. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01588-7 · Cited by 181
Chuzi, S., Tavora, F., Cruz, M., Costa, R., Chae, Y. K., Carneiro, B. A., & Giles, F. J. (2017) · Cancer Management and Research · doi:10.2147/cmar.s136818 · Cited by 181
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.274 · Cited by 180
Amin, A., Plimack, E. R., Ernstoff, M. S., Lewis, L. D., Bauer, T. M., McDermott, D. F., Carducci, M., Kollmannsberger, C., Rini, B. I., Heng, D. Y. C., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0420-0 · Cited by 180
Self-citationMajzner, R. G., Simon, J. S., Grosso, J. F., Martinez, D., Pawel, B. R., Santi, M., Merchant, M. S., Geoerger, B., Hezam, I., Marty, V., et al. (2017) · Cancer · doi:10.1002/cncr.30724 · Cited by 179
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
Braun, D. A., Burke, K. P., & Van Allen, E. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0066 · Cited by 179
Advances in immunotherapy delivery from implantable and injectable biomaterials
Leach, D. G., Young, S., & Hartgerink, J. D. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.02.016 · Cited by 179
Yoest, J. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s126227 · Cited by 176
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Emerging Nano‐/Microapproaches for Cancer Immunotherapy
Mi, Y., Hagan, C. T., Vincent, B. G., & Wang, A. Z. (2019) · Advanced Science · doi:10.1002/advs.201801847 · Cited by 177
Huo, J.-L., Wang, Y.-T., Fu, W.-J., Lu, N., & Liu, Z.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956090 · Cited by 176
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
Van den Eynde, B. J., van Baren, N., & Baurain, J.-F. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033635 · Cited by 175
The immune mechanisms of abscopal effect in radiation therapy
Grass, G. D., Krishna, N., & Kim, S. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2015.10.003 · Cited by 175
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 175
Immunotherapies: Exploiting the Immune System for Cancer Treatment
Koury, J., Lucero, M., Cato, C., Chang, L., Geiger, J., Henry, D., Hernandez, J., Hung, F., Kaur, P., Teskey, G., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/9585614 · Cited by 175
18F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma
Ito, K., Teng, R., Schöder, H., Humm, J. L., Ni, A., Michaud, L., Nakajima, R., Yamashita, R., Wolchok, J. D., & Weber, W. A. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.213652 · Cited by 174
Self-citationUnderstanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174
Development of immune checkpoint therapy for cancer
Fritz, J. M., & Lenardo, M. J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 175
Boussios, S., Seraj, E., Zarkavelis, G., Petrakis, D., Kollas, A., Kafantari, A., Assi, A., Tatsi, K., Pavlidis, N., & Pentheroudakis, G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.11.006 · Cited by 174
Survival of patients with advanced metastatic melanoma: The impact of novel therapies
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J. J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P., McArthur, G. A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.013 · Cited by 174
“Moreover, for PFS the combination treatment with PD1 inhibitors plus ipilimumab tends to be superior to PD1 inhibition alone, at least in certain patient subgroups (CheckMate067; CheckMate-069) [26].”
BackgroundSelf-citationThe role of neoantigens in response to immune checkpoint blockade
Riaz, N., Morris, L., Havel, J. J., Makarov, V., Desrichard, A., & Chan, T. A. (2016) · International Immunology · doi:10.1093/intimm/dxw019 · Cited by 175
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
Morrissey, K., Yuraszeck, T., Li, C., Zhang, Y., & Kasichayanula, S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12391 · Cited by 171
Wheeler, L. A., Manzanera, A. G., Bell, S. D., Cavaliere, R., McGregor, J. M., Grecula, J. C., Newton, H. B., Lo, S. S., Badie, B., Portnow, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now002 · Cited by 172
Ascierto, P. A., Agarwala, S., Botti, G., Cesano, A., Ciliberto, G., Davies, M. A., Demaria, S., Dummer, R., Eggermont, A. M., Ferrone, S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1070-y · Cited by 173
“1 (Response rate: 61 versus 11%, respectively) and progression free survival [73].”
BackgroundSelf-citationUtility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Diggs, L. P., & Hsueh, E. C. (2017) · Biomarker Research · doi:10.1186/s40364-017-0093-8 · Cited by 173
“The ORR+ and ORR- are 72 and 55%, respectively and the associated SENS and SPEC for this bioassay are 57 and 54%, respectively [25, 27, 28].”
BackgroundCurrent and Future Treatment Strategies for Rhabdomyosarcoma
Chen, C., Dorado Garcia, H., Scheer, M., & Henssen, A. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01458 · Cited by 172
“, immune checkpoint blockade in metastatic melanoma (168, 169, 172, 174, 175)] and systematic analysis of clinical trials of related families of childhood cancers [e.”
BackgroundReschke, R., Yu, J., Flood, B. A., Higgs, E. F., Hatogai, K., & Gajewski, T. F. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003521 · Cited by 169
Sanmamed, M. F., Rodriguez, I., Schalper, K. A., Oñate, C., Azpilikueta, A., Rodriguez-Ruiz, M. E., Morales-Kastresana, A., Labiano, S., Pérez-Gracia, J. L., Martín-Algarra, S., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3510 · Cited by 170
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
Dougan, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01547 · Cited by 170
Chiu, D. K.-C., Yuen, V. W.-H., Cheu, J. W.-S., Wei, L. L., Ting, V., Fehlings, M., Sumatoh, H., Nardin, A., Newell, E. W., Ng, I. O.-L., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.074 · Cited by 170
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0195-4 · Cited by 169
Naik, G. S., Waikar, S. S., Johnson, A. E. W., Buchbinder, E. I., Haq, R., Hodi, F. S., Schoenfeld, J. D., & Ott, P. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0512-5 · Cited by 169
Self-citationTargets for immunotherapy of liver cancer
Greten, T. F., & Sangro, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.007 · Cited by 168
“20 CTLA4 alone and 44% for anti-PD1 alone) [37].”
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M., Goebeler, M., Meierjohann, S., Houben, R., & Schrama, D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1403-9 · Cited by 153
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Vandekerkhove, G., Todenhöfer, T., Annala, M., Struss, W. J., Wong, A., Beja, K., Ritch, E., Brahmbhatt, S., Volik, S. V., Hennenlotter, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1140 · Cited by 166
Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges
Kyi, C., & Postow, M. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0002 · Cited by 165
Self-citationImmuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
Anagnostou, V., Yarchoan, M., Hansen, A. R., Wang, H., Verde, F., Sharon, E., Collyar, D., Chow, L. Q. M., & Forde, P. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3065 · Cited by 166
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Thanindratarn, P., Dean, D. C., Nelson, S. D., Hornicek, F. J., & Duan, Z. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100221 · Cited by 165
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Wu, X., Giobbie-Hurder, A., Liao, X., Connelly, C., Connolly, E. M., Li, J., Manos, M. P., Lawrence, D., McDermott, D., Severgnini, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0206 · Cited by 164
Self-citationPreserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy
Liu, Y., & Zheng, P. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.003 · Cited by 162
“Despite these challenges, there is a continuing interest in targeting CTLA-4 for cancer immunotherapy as Ipilimumab has shown to improve therapeutic response to anti-PD-1 antibody, as evidenced by improved overall survival, objective response rate and progression-free survival [42-48].”
BackgroundStructural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
Ramagopal, U. A., Liu, W., Garrett-Thomson, S. C., Bonanno, J. B., Yan, Q., Srinivasan, M., Wong, S. C., Bell, A., Mankikar, S., Rangan, V. S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617941114 · Cited by 162
Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency
Evans, V. A., van der Sluis, R. M., Solomon, A., Dantanarayana, A., McNeil, C., Garsia, R., Palmer, S., Fromentin, R., Chomont, N., Sékaly, R.-P., et al. (2018) · AIDS · doi:10.1097/qad.0000000000001849 · Cited by 162
Abdel-Rahman, O., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O., & Giryes, A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1296765 · Cited by 161
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Lee, H., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Buchbinder, E. I., Haq, R., Tolaney, S., Barroso-Sousa, R., Zhang, K., Donahue, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0208 · Cited by 161
“Anti–CTLA-4 monotherapy is associated with primary thyroid disorders (4,20).”
Self-citationKhan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2238 · Cited by 161
Mushti, S. L., Mulkey, F., & Sridhara, R. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1902 · Cited by 161
Su, Q., Zhu, E. C., Wu, J.-B., Li, T., Hou, Y.-L., Wang, D.-Y., & Gao, Z.-H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00108 · Cited by 161
“Some study has shown that PD-1 inhibitors have more potential to activate T cells toward a large spectrum of tissue-specific antigens including lung parenchyma than CTLA4 inhibitors (34, 35).”
BackgroundSmalley, I., Chen, Z., Phadke, M., Li, J., Yu, X., Wyatt, C., Evernden, B., Messina, J. L., Sarnaik, A., Sondak, V. K., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1694 · Cited by 161
Advances in immunotherapy for melanoma
Redman, J. M., Gibney, G. T., & Atkins, M. B. (2016) · BMC Medicine · doi:10.1186/s12916-016-0571-0 · Cited by 160
“While 36 % of patients had treatment discontinuation on Checkmate-069, 67 % of these patients had an objective response that continued on past discontinuation of therapy [37, 53].”
BackgroundResultInfluentialBang, A., Wilhite, T. J., Pike, L. R. G., Cagney, D. N., Aizer, A. A., Taylor, A., Spektor, A., Krishnan, M., Ott, P. A., Balboni, T. A., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.02.003 · Cited by 159
Self-citationMeasuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma
Shoushtari, A. N., Friedman, C. F., Navid-Azarbaijani, P., Postow, M. A., Callahan, M. K., Momtaz, P., Panageas, K. S., Wolchok, J. D., & Chapman, P. B. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2391 · Cited by 158
Self-citationCardiovascular Toxicities Associated with Cancer Immunotherapies
Wang, D. Y., Okoye, G. D., Neilan, T. G., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 157
Checkpoint inhibitors in breast cancer – Current status
Dyhl-Polk, A., Svane, I. M., Andersson, M., & Nielsen, D. L. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.008 · Cited by 173
Yu, Y., Schleich, K., Yue, B., Ji, S., Lohneis, P., Kemper, K., Silvis, M. R., Qutob, N., van Rooijen, E., Werner-Klein, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.002 · Cited by 156
“…for melanoma (and possibly other cancer entities) that integrates effective suppression of Braf/MEK oncogenic signaling (Robert et al., 2015), immune therapy via checkpoint blockade (Postow et al., 2015), and, in a presumably synergistic fashion, senescence restoration via demethylase inhibition.”
BackgroundTargeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
Deken, M. A., Gadiot, J., Jordanova, E. S., Lacroix, R., van Gool, M., Kroon, P., Pineda, C., Geukes Foppen, M. H., Scolyer, R., Song, J.-Y., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1238557 · Cited by 153
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
Collins, M., Michot, J., Danlos, F. X., Mussini, C., Soularue, É., Mateus, C., Loirat, D., Buisson, A., Rosa, I., Lambotte, O., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx403 · Cited by 163
Self-citationTheurich, S., Rothschild, S. I., Hoffmann, M., Fabri, M., Sommer, A., Garcia-Marquez, M. A., Thelen, M., Schill, C., Merki, R., Schmid, T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0156 · Cited by 156
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
Lin, X., Lu, X., Luo, G., & Xiang, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111876 · Cited by 160
Kluger, H. M., Zito, C. R., Turcu, G., Baine, M. K., Zhang, H., Adeniran, A., Sznol, M., Rimm, D. L., Kluger, Y., Chen, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3146 · Cited by 152
Cutaneous Melanoma—A Review in Detection, Staging, and Management
Hartman, R. I., & Lin, J. Y. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.09.005 · Cited by 167
Bailey, C. M., Liu, Y., Liu, M., Du, X., Devenport, M., Zheng, P., Liu, Y., & Wang, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150846 · Cited by 151
“…irAEs resulting from anti–PD-1/anti–PD-L1 mAbs are generally less severe than those from anti–CTLA-4 mAbs (16, 17), PD-1/PD-L1 blockade does lead to significant irAEs and administering anti–PD-1 mAbs concurrently with anti–CTLA-4 mAbs substantially worsens irAE incidence and severity (5, 18–21).”
Buchbinder, E. I., Dutcher, J. P., Daniels, G. A., Curti, B. D., Patel, S. P., Holtan, S. G., Miletello, G. P., Fishman, M., Gonzalez, R. C., Clark, J. I., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0522-3 · Cited by 156
Self-citationA Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors
Chhabra, N., & Kennedy, J. M. (2021) · Journal of Medical Toxicology · doi:10.1007/s13181-021-00833-8 · Cited by 164
Wang, W., Lie, P., Guo, M., & He, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30678 · Cited by 146
Hematologic complications of immune checkpoint inhibitors
Kroll, M. H., Hernandez, C. M. R., & Yee, C. (2021) · Blood · doi:10.1182/blood.2020009016 · Cited by 163
Cano‐Mejia, J., Burga, R. A., Sweeney, E. E., Fisher, J. P., Bollard, C. M., Sandler, A. D., Cruz, C. C., & Fernandes, R. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.10.015 · Cited by 148
Wang, T., Zheng, N., Luo, Q., Jiang, L., He, B., Yuan, X., & Shen, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01235 · Cited by 146
“Immune checkpoint blockade (ICB) immunotherapy targeting intrinsic downregulators of immunity, such as cytotoxic Tlymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death ligand 1 (PD-L1) has shown durable clinical responses and recently been a source of promising new…”
BackgroundHou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 145
“(3) Structure the TME through the cellular and molecular immunosuppressive network mediated by MDSCs (Figure 2).”
BackgroundZappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Senbabaoglu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.009 · Cited by 142
Self-citationScott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142
Abdel-Rahman, O., ElHalawani, H., & Fouad, M. (2016) · Future Oncology · doi:10.2217/fon.15.222 · Cited by 143
Vieira, T., Antoine, M., Hamard, C., Fallet, V., Duruisseaux, M., Rabbe, N., Rodenas, A., Cadranel, J. L., & Wislez, M. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.013 · Cited by 148
Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers
Majzner, R. G., Heitzeneder, S., & Mackall, C. L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.03.002 · Cited by 151
Forget, M., Haymaker, C., Hess, K. R., Meng, Y. J., Creasy, C. A., Karpinets, T. V., Fulbright, O. J., Roszik, J., Woodman, S. E., Kim, Y. U., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3649 · Cited by 145
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140
Beug, S. T., Beauregard, C. E., Healy, C., Sanda, T., St-Jean, M., Chabot, J., Walker, D. E., Mohan, A., Earl, N., Lun, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms14278 · Cited by 140
Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms
Gholami, M. D., Kardar, G. A., Saeedi, Y., Heidari, S., Garssen, J., & Falak, R. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.10.002 · Cited by 161
Ma, K., Lu, Y., Jiang, S., Tang, J., Li, X., & Zhang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01430 · Cited by 153
Azevedo, R., Shoshan, E., Whang, S., Markel, G., Jaiswal, A. R., Liu, A. J., Curran, M. A., Travassos, L. R., & Bar‐Eli, M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1846915 · Cited by 173
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 162
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 139
d’Izarny-Gargas, T., Dürrbach, A., & Zaidan, M. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15811 · Cited by 148
Lussier, D. M., Alspach, E., Ward, J. P., Miceli, A. P., Runci, D., White, J. M., Mpoy, C., Arthur, C. D., Kohlmiller, H. N., Jacks, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102611118 · Cited by 152
The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform
Schachtschneider, K. M., Schwind, R. M., Newson, J. L., Kinachtchouk, N., Rizko, M., Mendoza-Elias, N., Grippo, P. J., Principe, D. R., Park, A. J., Overgaard, N. H., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00190 · Cited by 150
Endocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 136
Ocular and orbital side-effects of checkpoint inhibitors: a review article
Antoun, J., Titah, C., & Cochereau, I. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000296 · Cited by 137
Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies
Liu, P., Huo, T., & Miksad, R. A. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1666805 · Cited by 140
Checkpoint inhibitors in hematological malignancies
Ok, C. Y., & Young, K. H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0474-3 · Cited by 136
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Pinter, M., Scheiner, B., & Pinato, D. J. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00147-4 · Cited by 155
Metadata
- Authors
- Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D., & Hodi, F. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Université Paris-Sud (FR)
- Beth Israel Deaconess Medical Center (US)
- From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) — all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) — all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D....
- Prisma Health (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-21
- Volume
- 372
- Issue
- 21
- Pages
- 2006-2017
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5744258
- OpenAlex
- W2128758225
- Cited by
- 2,781
- References
- 28
- Citations by year
- 2026: 53 · 2025: 91 · 2024: 131 · 2023: 175 · 2022: 174 · 2021: 206 · 2020: 261 · 2019: 277 · 2018: 372 · 2017: 449 · 2016: 402 · 2015: 183
- FWCI
- 204.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, metastatic melanoma, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, objective response rate, progression-free survival, BRAF V600 mutation, immune-related adverse events, first-line therapy, dose escalation, complete response, duration of response
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Disease-Free Survival, Tumor Burden, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.